Impact of a Novel Infectious Disease on Consumption, Supply Chains and Business Activities
First written in FY2020. 9 of 13 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
53 other companies' latest entry also says "Mitigated".
- FY2024MitigatedAnnual report
「The Japanese economy during the consolidated fiscal year under review continued to face an uncertain outlook. Economic activity was moving toward normalization following the reclassification of COVID-19 under the Infectious Diseases Control Law, but raw material and energy prices remained high and exchange rates fluctuated.」
The disclosure states that economic activity is normalizing following the reclassification of COVID-19 under the Infectious Diseases Control Law and that the impact of emerging infectious diseases on business activities is easing compared with before. - FY2024-Q3RestatedAnnual report
「During the third quarter of the fiscal year under review, economic activity in Japan continued to show signs of returning to normal following the reclassification of COVID-19 under the Infectious Diseases Control Law. However, the outlook remained uncertain due to soaring raw material and energy prices, foreign exchange fluctuations, and geopolitical risks.」
While economic activity is normalizing following the reclassification of COVID-19 under the Infectious Diseases Control Law, the disclosure states that uncertainty remains after the pandemic due to factors including higher raw material and energy prices. - FY2024-Q1MitigatedAnnual report
「During the first quarter of the fiscal year under review, economic activity in Japan continued to show signs of returning to normal following the reclassification of COVID-19 under the Infectious Diseases Control Law. However, the outlook remained uncertain due to soaring raw material and energy prices and foreign exchange fluctuations.」
As economic activity normalizes following the reclassification of COVID-19 under the Infectious Diseases Control Law, the disclosure describes the impact of emerging infectious diseases on business activities as easing compared with before. - FY2023-Q3RestatedAnnual report
「We have continued to implement thorough measures against the novel coronavirus disease, working to ensure employee safety and the stable production and supply of products.」
Even as restrictions on movement are eased, we continue infection control measures, efforts to ensure employee safety and stable product supply. - FY2023-Q2RestatedAnnual report
「We have continued to implement thorough measures against the novel coronavirus disease, working to ensure employee safety and the stable production and supply of products.」
Even as restrictions on movement are eased, we continue infection control measures, efforts to ensure employee safety and stable product supply. - FY2023-Q1RestatedAnnual report
「We have continued to implement thorough measures against the novel coronavirus disease, working to ensure employee safety and the stable production and supply of products.」
Even as restrictions on activities are eased, we continue infection control measures, efforts to ensure employee safety and stable product supply. - FY2022-Q3RestatedAnnual report
「In response to the novel coronavirus disease, we thoroughly implemented measures to prevent infection and its spread, centered on the infection control headquarters, while taking steps to ensure employee safety as our top priority. At our production and logistics sites, we also thoroughly implemented hygiene management and measures against infection risks, while continuing efforts to ensure stable production and supply of products.」
Although the impact of COVID-19 continues, we continue the task force, infection prevention and control, employee safety and measures to ensure stable supply. - FY2022-Q2RestatedAnnual report
「In response to the novel coronavirus disease, we thoroughly implemented measures to prevent infection and its spread, centered on the infection control headquarters, while taking steps to ensure employee safety as our top priority. At our production and logistics sites, we also thoroughly implemented hygiene management and measures against infection risks, while continuing efforts to ensure stable production and supply of products.」
Although the impact of COVID-19 continues, we continue the task force, infection prevention and control, employee safety and measures to ensure stable supply. - FY2022-Q1RestatedAnnual report
「In addition, centered on the task force for responding to COVID-19, we have thoroughly implemented measures to prevent infection and its spread, while making employee safety our top priority. At production and logistics sites, we have thoroughly implemented hygiene controls and measures against infection risks and continued to work to ensure stable production and supply of products.」
We continue measures centered on the task force to prevent infection and its spread, ensure employee safety, maintain hygiene at production and logistics sites and ensure stable supply. - FY2021-Q3RestatedAnnual report
「Since the previous fiscal year, we established a task force to respond to COVID-19 and have continued to thoroughly implement measures to prevent infection and its spread, while making employee safety our top priority. At production and logistics sites, we have thoroughly implemented hygiene controls and measures against infection risks and continued to work to ensure stable production and supply of products.」
We continue measures centered on the task force to prevent infection and its spread, ensure employee safety, maintain hygiene at production and logistics sites and ensure stable supply. - FY2021-Q2RestatedAnnual report
「Since the previous fiscal year, we established a task force to respond to COVID-19 and have continued to thoroughly implement measures to prevent infection and its spread, while making employee safety our top priority. At production and logistics sites, we have thoroughly implemented hygiene controls and measures against infection risks and continued to work to ensure stable production and supply of products.」
We continue measures centered on the task force to prevent infection and its spread, ensure employee safety, maintain hygiene at production and logistics sites and ensure stable supply. - FY2021-Q1MitigatedAnnual report
「Since the previous fiscal year, we established a task force to respond to COVID-19 and have thoroughly implemented measures to prevent infection and its spread, while making employee safety our top priority. At production and logistics sites, we also thoroughly implemented hygiene controls and measures against infection risks and worked to ensure stable production and supply of products.」
Although the impact of COVID-19 itself continues, the disclosure specifically describes the establishment of a task force, infection prevention and control, employee safety, hygiene management at production and logistics sites and measures to ensure stable supply. - FY2020MaterialisedAnnual report
「During the fiscal year under review, Japan's economy remained on a moderate recovery trend, supported by continued improvement in corporate earnings and employment and income conditions. However, in addition to developments in overseas economies, including the US-China trade friction, the impact of the global spread of COVID-19 became more serious, leaving the outlook extremely uncertain.」
The global spread of COVID-19 and its serious impact on economic and social activity were described as risks that had actually materialized. Specific risks included the infectious disease response manual, a decline in consumption, supply chain disruptions and the possibility of infection among employees and business partners.